The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Monday, 27th May 2013.

TZ has logged significant progress this week, locking in the initial locations for the first stage roll out of its A.D.A.M. Parcel Locker System while signing on Fastway Couriers to use its Parcel Locker Network during a 12 month trial.

To top it off, the company has received a new purchase order from Singapore Post "for a material and significant number of smart lockers."

TZ Limited will be presenting at the Proactive Investors One2One Forum in Sydney on 4 June 2013. Click HERE to register.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.

This along with new soil sampling geochemistry have allowed the company to define a greater than 1 kilometre long corridor of mineralisation at the southwestern end of the 2 kilometre long Ulupong structure.

"The Ulupong discovery is starting to look very significant. High-grade gold, in outcropping veins, is supported by strong soil anomalies over a one kilometre strike length," managing director Jon Dugdale said.

"We are excited at the prospect of drilling this new discovery, along with the other high grade, near surface targets at Pica and Japanese Tunnels."

The sampling was carried out over sub-cropping quartz-sulphide boulders in the Bigaan-Ulupong area about 800 metres along strike to the northeast of the ULOC 4 trench where a recent result of 1.4 metres at 1.26 g/t gold including 0.3 metres at 5.3 g/t gold was produced across northern extensions of the ULOC 4 vein.

Previous sampling across the vein at ULOC 4 intersected 0.45 metres at 23.39 g/t gold while sampling along the vein produced results of 19 metres at 9.77 g/t gold including 7 metres at 23.58 g/t gold.

Drilling is now planned to test the high-grade veins and soil anomalies at Ulupong as part of the next phase of drilling, which is expected to be funded by the Rights Issue of three new shares priced at $0.01 each for every two shares held by shareholders to raise up to $2.8 million.

This is partially and conditionally underwritten by Patersons Securities to $550,000.

Batangas

Batangas, located 120 kilometres south of Manila, comprises two key gold prospects, Archangel and Lobo, which have combined JORC Mineral Resources estimates of 5.78 million tonnes at 2.2 grams per tonne gold and 3.3g/t silver for 408,000 ounces of gold and 606,000 ounces of silver.

The bulk of resources are currently located at Archangel where surface stockwork gold mineralisation hosted by shallow dipping andesitic volcanics remains open to the east and west

Red Mountain has recently discovered four new, high-grade, near surface, epithermal gold vein zones at Lobo, Batangas, that will be the focus of further drilling with the objective of upgrading gold Mineral Resources and significantly enhancing the economics of a potential gold operation at the project.

Recent diamond drilling at Lobo had returned assays of 5 metres at 4.28g/t gold and 15.75g/t silver from 22.4 metres, including 1.3 metres at 9.49g/t gold and 21.5g/t silver, and 1.7 metres at 4.4g/t gold from 58.1 metres.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.

Stubbs acquired the shares in February and in May and now holds 8,268,445 shares in Triton.

Triton shares have been firm of late, up 12.7% since 13 May.

During the last quarter, Triton confirmed the presence of graphite in the Balama prospects in Mozambique's prolific Graphite region of the Cabo Delgado Province.

It focused its initial exploration to defining level 1 and 2 target zones.

Exploration program work will be expanded to incorporate the remaining levels.

The initial interpretation is that the graphite mineralisation continues on the North-East trend, extending up from the Syrah Resources Ltd (ASX SYR) large and high grade graphite deposits.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.

Current assets, including cash, cash equivalents, collateral advance, and prepaid expenses, rose to $16.9 million as of March 31, from $14.6 million as of December 31, the West Haven, Connecticut-based company said in a statement on Wednesday.

NanoViricides, which is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza and HIV, estimated that it currently has sufficient cash in hand to support operations for at least two years at the current rate of cash expenditure, according to the statement.

NanoViricides also estimated that it has sufficient cash in hand to support "initial human clinical trials of its first drug candidate, a broad-spectrum anti-influenza drug in its FluCide&trade program," it said.

The shares rose 1.2 percent to 61.7 cents at 9:56 a.m. They traded as high as 70 cents and as low as 58 cents in earlier trading. The stock gained 28 percent since the beginning of the year through Tuesday.

During the quarter, the company spent $1.4 million in research and development expenses, or R&D, and $831,400 in general and administrative expenses, or G&A, including stock-based expenses. The company's rate of expenditure was in line with the company's budgeted targets.

The company also said it had raised $6 million from three family offices and a charitable foundation in February, as announced previously. The company announced full retirement of its Series C convertible preferred stock held by Seaside 88, LP, with a cash payment of approximately $2.01 million.

NanoViricides said that all of its drug development programs are progressing satisfactorily. The company is advancing its oral broad-spectrum anti-influenza drug candidate, NV-INF-2, towards IND-enabling studies.

"This may be the first ever nanomedicine drug of any kind that is active when administered orally. This drug is being developed for out-patient influenza cases, and may also be useful for influenza prophylaxis, as in use for the protection of health care workers," the company said.

The company also continues to develop its injectable anti-influenza drug, NV-INF-1, towards IND-enabling studies. "This drug candidate has much greater activity than the oral drug, and is intended for use in hospitalized patients with influenza or potentially influenza-like illness. The company believes it will be useable in immuno-compromised populations, and may receive an orphan drug classification for this indication," the statement said.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

The company, which is focused on developing products to treat inflammatory diseases and biodefense countermeasures, says the patent claims encompass composition of matter and methods for the technology, which is exclusively licensed to Soligenix by the University of Colorado.

For vaccines that are intended for long-term stockpiling, such as for use in biodefense or in pandemic situations, Soligenix has said that the use of ThermoVax, which has been tested in combination with the company's RiVax and VeloThrax vaccines, can lead to easier storage and the distribution of strategic national stockpile vaccines in emergency situations.

This is because the technology allows the production of thermostable vaccines that do not require storage at refrigerated temperatures.

The patent claims granted Wednesday describe methods of preparing an "immunologically-active adjuvant-bound", thermostable, freeze dried vaccine composition, in which the vaccine uses conventional adjuvants comprised of aluminum salts, the company said.

It added that aluminum salts are commonly used as adjuvants in many vaccines, including those administered to children.

ThermoVax was developed specifically to overcome the problems that are encountered with freeze-drying vaccines that contain aluminum adjuvants while simultaneously engineering them to withstand extremes of temperature.

"The granting of the thermostabilization patent is a significant milestone for the ThermoVax program and is a critical component in our commercialization strategy for vaccines that can avoid the increased costs and logistical burdens associated with cold chain storage and distribution," said president and CEO, Christopher J. Schaber, in the release Wednesday.

"We expect that the introduction of an effective technology for long-term stabilization of vaccines has the potential to be a major advance in the national effort to develop effective countermeasures and therapies for significant biothreats and emerging pathogens."

Schaber also said the company has initiated discussions with "a number" of vaccine companies and non-profit organizations regarding the potential for collaboration on heat-stable versions of their vaccine candidates.

Soligenix is also working to advance its biotherapeutics business, where it is set to start a phase 2 randomized, double blind, placebo-controlled study of SGX942 - its lead compound - for oral mucositis in head and neck cancer patients in the second half of this year. In phase 1 trials, it was shown to reduce the severity and duration of oral mucositis and induce anti-inflammatory activity.

Shares of the company were trading at $1.21 early Wednesday, with its shares more than doubling year-to-date.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

The assays are from an infill drilling program designed to convert the C Zone and near-surface inferred resources into the higher indicated category, as well as from three additional holes done as part of a hydrogeological drilling campaign.

The results from the main zone include near surface intercepts of 7.5 metres at 3.82 g/t gold from 36 metres depth, and 25 metres at 1.42 g/t gold from 152 metres depth, including 6 metres at 4.18 g/t gold in a hole located on the eastern edge of the proposed open pit, outside the current indicated resource area.

Hole TL13-331 also hit 21 metres of 0.87 g/t gold from 24 to 45 metres, including 3.0 metres at 3.64 g/t gold.

The company said that two of the above holes are significant due to their near-surface location within a "sparsely drilled" area between the eastern and centre pits, representing a potential reduction of the overall waste to ore stripping ratios on the main zone of the project.

Treasury also reported Wednesday results from the C Zone, which is located around 30 metres behind the main zone area, with holes showing intercepts of 13 metres at 0.94 g/t gold from 70.5 metres, and 8.5 metres at 1.52 g/t gold from 260 metres depth.

The gold company has been defining near surface resources at the C Zone since drilling started in the region late last year. Treasury believes the area has the potential to increase the current open pit mineable resource at Goliath, and reduce the overall waste-to-ore stripping ratios.

Since finishing the drilling program, Treasury has been working on a gap analysis to determine the location of the holes required to upgrade all ounces within the current open pit design, including both the main and C zones.

A new resource update will follow, which will be used to support a full feasibility study at the project, while the company also works on wrapping up its environmental impact statement - scheduled for later this year.

Earlier this month, Treasury closed the final tranche of a non-brokered private placement financing, raising a total of $1.78 million in the offering for the advancement of its Goliath gold project.

The project boasts near-term production potential, with the company forecasting production start-up in late 2015, with average annual life-of-mine output of around 80,000 gold equivalent ounces at cash costs of $698 an ounce.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.